These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 2116585)

  • 21. Defining the patient group for cost-effective withdrawal of antihypertensive therapy.
    Krakoff LR; Wassertheil-Smoller S
    Pharmacoeconomics; 1995 Mar; 7(3):221-8. PubMed ID: 10155311
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Pharmacotherapy of hypertension. How much can safely be saved?].
    Anlauf M
    MMW Fortschr Med; 2004 Apr; 146(15):57-8. PubMed ID: 15373022
    [No Abstract]   [Full Text] [Related]  

  • 23. Changing the problem to fit the solution: Johannesson and Weinstein's (mis) application of economics to real world problems.
    Birch S; Gafni A
    J Health Econ; 1993 Dec; 12(4):469-76. PubMed ID: 10131757
    [No Abstract]   [Full Text] [Related]  

  • 24. Serving patient needs while implementing cost effectiveness programs in health care administration.
    Tootelian DH
    Health Mark Q; 1994; 11(3-4):161-73. PubMed ID: 10137013
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cost-benefit and cost-effectiveness analysis of drug therapy.
    Dao TD
    Am J Hosp Pharm; 1985 Apr; 42(4):791-802. PubMed ID: 3925768
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A guide to economic evaluation: methods for cost-effectiveness analysis of person-level data.
    Hoch JS; Smith MW
    J Trauma Stress; 2006 Dec; 19(6):787-97. PubMed ID: 17195977
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cost-effectiveness of antihypertensive agents in patients with reduced left ventricular function.
    Arnold RJ; Kaniecki DJ; Frishman WH
    Pharmacotherapy; 1994; 14(2):178-84. PubMed ID: 8197036
    [TBL] [Abstract][Full Text] [Related]  

  • 28. How to perform a cost-effectiveness analysis with surrogate endpoint: renal denervation in patients with resistant hypertension (DENERHTN) trial as an example.
    Bulsei J; Darlington M; Durand-Zaleski I; Azizi M;
    Blood Press; 2018 Apr; 27(2):66-72. PubMed ID: 29069927
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The cost-effectiveness of the switch towards more expensive antihypertensive drugs.
    Johannesson M
    Health Policy; 1994 Mar; 28(1):1-13. PubMed ID: 10136603
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Hypertension and current issues in compliance and patient outcomes.
    Zyczynski TM; Coyne KS
    Curr Hypertens Rep; 2000 Dec; 2(6):510-4. PubMed ID: 11062595
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Opportunity costs and uncertainty in the economic evaluation of health care interventions.
    Sendi P; Gafni A; Birch S
    Health Econ; 2002 Jan; 11(1):23-31. PubMed ID: 11788979
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Determinants of Change in the Cost-effectiveness Threshold.
    Paulden M; O'Mahony J; McCabe C
    Med Decis Making; 2017 Feb; 37(2):264-276. PubMed ID: 27553208
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cost-effectiveness issues in hypertension control.
    Schueler K
    Can J Public Health; 1994; 85 Suppl 2():S54-6. PubMed ID: 7804952
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Potential health impact and cost-effectiveness of drug therapy for prehypertension.
    Chen T; Yu D; Cornelius V; Qin R; Cai Y; Jiang Z; Zhao Z
    Int J Cardiol; 2017 Aug; 240():403-408. PubMed ID: 28501349
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Therapy of hypertension 1996. Effectiveness, tolerance, cost-benefit aspects].
    Rahn KH
    Med Klin (Munich); 1996 Jun; 91(6):380-3. PubMed ID: 8767312
    [No Abstract]   [Full Text] [Related]  

  • 36. Cost-effectiveness of irbesartan/hydrochlorothiazide in patients with hypertension: an economic evaluation for Sweden.
    Ekman M; Bienfait-Beuzon C; Jackson J
    J Hum Hypertens; 2008 Dec; 22(12):845-55. PubMed ID: 18633426
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The influence of absolute cardiovascular risk, patient utilities, and costs on the decision to treat hypertension: a Markov decision analysis.
    Montgomery AA; Fahey T; Ben-Shlomo Y; Harding J
    J Hypertens; 2003 Sep; 21(9):1753-9. PubMed ID: 12923409
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cost-effectiveness league tables: valuable guidance for decision makers?
    Mauskopf J; Rutten F; Schonfeld W
    Pharmacoeconomics; 2003; 21(14):991-1000. PubMed ID: 13129413
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Cost-benefit of treating hypertension.
    Jönsson BG
    J Hypertens Suppl; 1994 Dec; 12(10):S65-70. PubMed ID: 7769494
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Pharmacoeconomics of hypertension control: basic principles of economic evaluation.
    Wilson TW; Chockalingam A; Quest DW
    J Hum Hypertens; 1996 Feb; 10 Suppl 2():S19-22. PubMed ID: 8868039
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.